ARCHIVES

Includes June issue of Business & Regulatory Report.

This article is from The Cancer Letter archive.

Vol. 28 No. 26 | June 28, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Norman Sharpless Named Director of UNC Lineberger

September 6, 2013

House-Senate Conferees agree On NCI Total for FY’89, Then Cut It $19 Million

August 26, 1988

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

IOM Report: Seek More Comment From Public On Priorities, NIH Told

July 17, 1998

Trials Suspended At Oklahoma Over Study Of Cancer Vaccine.

July 14, 2000

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992